Pharmacogenomics of Hypertension Personalized Medicine (PGX-HT)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 300 participants.

Also called NCT03249285

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 300 participants (planned count) (from the registry)
Sponsor
Ospedale San Raffaele (from the registry)
Registry
  • NCT NCT03249285
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Italy (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03249285. Randomized; no masking; primary purpose treatment. Start 2016-03 (registry gives no type); primary completion 2018-03 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Pharmacogenomics of Hypertension Personalized Medicine (PGX-HT)
Acronym
PGX-HT
Condition
Hypertension
Intervention (Drug)
Peri
Intervention (Drug)
HCTZ
Lead sponsor
Ospedale San Raffaele (class: other)

Record details

Record id
cardio:ct-nct03249285
Content hash
62fe5385b6085a85973002b4296925090396e60538cb20fc752540485e13c776